Vimarsana
Biggest News Aggregation in the World

Page 2 - Advanced Diagnostics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Advanced Diagnostics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Advanced Diagnostics Today - Breaking & Trending Today

212,935 Shares in NeoGenomics, Inc. (NASDAQ:NEO) Acquired by Lisanti Capital Growth LLC - Vimarsana News

212,935 Shares in NeoGenomics, Inc. (NASDAQ:NEO) Acquired by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC acquired a new position in shares of NeoGenomics, Inc. (NASDAQ:NEO – Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 212,935 shares of the medical research company’s stock, valued at approximately $3,445,000. Lisanti Capital Growth LLC owned approximately 0.17% […]

Handelsbanken Fonder AB Has $322,000 Stock Position in NeoGenomics, Inc. (NASDAQ:NEO) - Vimarsana News

Handelsbanken Fonder AB Has $322,000 Stock Position in NeoGenomics, Inc. (NASDAQ:NEO)

Handelsbanken Fonder AB lifted its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 7.0% during the fourth quarter, Holdings Channel.com reports. The firm owned 19,900 shares of the medical research company’s stock after acquiring an additional 1,300 shares during the period. Handelsbanken Fonder AB’s holdings in NeoGenomics were worth $322,000 as of […]

NeoGenomics (NASDAQ:NEO) Stock Rating Reaffirmed by Benchmark - Vimarsana News

NeoGenomics (NASDAQ:NEO) Stock Rating Reaffirmed by Benchmark

Benchmark reaffirmed their buy rating on shares of NeoGenomics (NASDAQ:NEO – Free Report) in a research note issued to investors on Wednesday morning, Benzinga reports. The firm currently has a $18.00 price objective on the medical research company’s stock. Other research analysts also recently issued reports about the company. William Blair restated an outperform rating […]

NeoGenomics (NASDAQ:NEO) Receives "Buy" Rating from Benchmark - Vimarsana News

NeoGenomics (NASDAQ:NEO) Receives "Buy" Rating from Benchmark

Benchmark reissued their buy rating on shares of NeoGenomics (NASDAQ:NEO – Free Report) in a report released on Wednesday, Benzinga reports. The brokerage currently has a $18.00 price target on the medical research company’s stock. A number of other brokerages have also commented on NEO. Piper Sandler increased their price objective on NeoGenomics from $18.00 […]

NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by Mach 1 Financial Group LLC - Vimarsana News

NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by Mach 1 Financial Group LLC

Mach 1 Financial Group LLC lowered its position in NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 33.5% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 23,228 shares of the medical research company’s stock after selling 11,701 shares during the quarter. Mach 1 Financial Group LLC’s holdings in NeoGenomics were worth $376,000 as of […]